Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry

BJU International

Volumn 110, Issue 2, 2012, Pages 240-246

  Nilsson, Fredrik O L ^a   Linnér, Love ^b   Samuelsson, Eva ^c   Milsom, Ian ^a  

^a Dental and Pharmaceutical Benefits Agency   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Anticholinergic drugs; Cost effectiveness; Oxybutynin; Urgency urinary incontinence; Urinary incontinence

Indexed keywords

DARIFENACIN; FESOTERODINE; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE;

ARTICLE; CLINICAL EVALUATION; CLINICAL PRACTICE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; OUTCOME ASSESSMENT; PLACEBO EFFECT; PRESCRIPTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE;

CHOLINERGIC ANTAGONISTS; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; INCONTINENCE PADS; MANDELIC ACIDS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; URINARY INCONTINENCE, URGE;

EID: 84863459839     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10729.x     Document Type: Article

References (39)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002; 187: 116-26
2. Milsom I, Altman D, Herbison P et al. Epidemiology of urinary (UI) and faecal (FI) incontinence and pelvic organ prolapse (POP). In Abrams P, Cardozo L, Kouhry S, Wein A eds. Incontinence,Paris: Health Publications, 2009: 37-111
3. Ko Y, Lin SJ, Salmon JW, Bron MS. The impact of urinary incontinence on quality of life of the elderly. Am J Manag Care 2005; 11: S103-11 (Pubitemid 41022718)
4. Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997; 50: 100-10
5. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006; (4): CD003781
6. Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol 2004; 22: 251-6 (Pubitemid 41406544)
7. Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005; 95: 81-5 (Pubitemid 350020875)
8. Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002; 8: S608-15 (Pubitemid 36050142)
9. Kelleher CJ, Tubaro A, Wang JT, Kopp Z. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int 2008; 102: 56-61 (Pubitemid 351799457)
10. Khullar V, Hill S, Laval KU, Schiotz HA, Jonas U, Versi E. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 2004; 64: 269-75 (Pubitemid 39092452)
11. Yamaguchi O, Marui E, Kakizaki H et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int 2007; 100: 579-87 (Pubitemid 47205477)
12. Wettermark BH, Fored N, Leimanis CM et al. The new Swedish Prescribed Drug Register - opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-35
13. Getsios D, Caro JJ, Ishak KJ et al. Oxybutynin extended release and tolterodine immediate release: a health economic comparison. Clin Drug Investig 2004; 24: 81-8 (Pubitemid 38316597)
14. Hakkaart L, Verboom P, Phillips R, Al MJ. The cost utility of solifenacin in the treatment of overactive bladder. Int Urol Nephrol 2009; 41: 293-8
15. Kobelt G, Jonsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn 1998; 17: 599-611 (Pubitemid 28499043)
16. Milsom I, Axelsen S, Kulseng-Hansen S, Mattiasson A, Nilsson CG, Wickstrom J. Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Acta Obstet Gynecol Scand 2009; 88: 693-9
17. O'Brien BJ, Goeree R, Bernard L, Rosner A, Williamson T. Cost-effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. Clin Ther 2001; 23: 2038-49 (Pubitemid 34073195)
18. Speakman M, Khullar V, Mundy A, Odeyemi I, Bolodeoku J. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin 2008; 24: 2173-9
19. Cardozo L, Thorpe A, Warner J, Sidhu M. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int 2010; 106: 506-14
20. Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001; 165: 1452-6 (Pubitemid 32410212)
21. SBU. Behandling av urininkontinens. SBU-Rapport Nr 143: Statens Beredning För Medicinsk Utvärdering. Stockholm: SBU, 2000
22. Linnér LS, Schiöler H, Samuelsson E, Milsom I, Nilsson F. Low persistence of anticholinergic drug use in Sweden. Eur J Clin Pharmacol 2010; 67: 535-6
23. SWEDIS. Swedish Drug Information System. 2010
24. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 385-96
25. Meek PD, Evang SD, Tadrous M, Roux-Lirange D, Triller DM, Gumustop B. Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig Dis Sci 2011; 56: 7-18
26. Milsom I. Lower urinary tract symptoms in women. Curr Opin Urol 2009; 19: 337-41
27. Samuelsson E, Mansson L, Milsom I. Incontinence aids in Sweden: users and costs. B JU Int 2001; 8 8: 893-8 (Pubitemid 34099016)
28. Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464-70 (Pubitemid 41188406)
29. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57: 414-21 (Pubitemid 32192963)
30. Brazier J, Czoski-Murray C, Roberts J, Brown M, Symonds T, Kelleher C. Estimation of a preference-based index from a condition-specific measure: the King's Health Questionnaire. Med Decis Making 2008; 28: 113-26
31. Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy 2006; 26: 1694-702 (Pubitemid 44885326)
32. Johannesson M, O'Conor RM, Kobelt-Nguyen G, Mattiasson A. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997; 80: 557-62 (Pubitemid 28316377)
33. Nygaard I. Clinical practice. Idiopathic urgency urinary incontinence. N Engl J Med 2010; 363: 1156-62
34. National Institute for Health and Clinical Excellence. Urinary Incontinence-the Management of Urinary Incontinence in Women. London: NICE, 2006
35. Kraus SR, Bavendam T, Brake T, Griebling TL. Vulnerable elderly patients and overactive bladder syndrome. Drugs Aging 2010; 27: 697-713
36. Uusvaara J, Pitkala KH, Kautiainen H, Tilvis RS, Strandberg TE. Association of anticholinergic drugs with hospitalization and mortality among older cardiovascular patients: a prospective study. Drugs Aging 2011; 28: 131-8
37. Kraus SR, Ruiz-Cerda JL, Martire D, Wang JT, Wagg AS. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 2010; 76: 1350-7
38. Griebling TL, Kraus SR, Richter HE, Glasser DB, Carlsson M. Tolterodine extended release is well tolerated in older subjects. Int J Clin Pract 2009; 63: 1198-204
39. Macdiarmid SA. Concomitant medications and possible side effects of antimuscarinic agents. Rev Urol 2008; 10: 92-8